{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:26:03Z","timestamp":1785878763804,"version":"3.56.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1124\/dmd.109.030999","type":"journal-article","created":{"date-parts":[[2010,6,2]],"date-time":"2010-06-02T00:49:29Z","timestamp":1275439769000},"page":"1471-1479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["In Vitro Metabolism, Permeability, and Efflux of Bazedoxifene in Humans"],"prefix":"10.1016","volume":"38","author":[{"given":"Li","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeongHee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"DeMaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Oganesian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Hultin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Scatina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bungay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Appavu","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.109.030999_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0169-409X(00)00128-9","article-title":"Caco-2 monolayers in experimental and theoretical predictions of drug transport","volume":"46","author":"Artursson","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/dmd.109.030999_bib2","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1124\/dmd.108.023861","article-title":"Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women","volume":"37","author":"Chandrasekaran","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.030999_bib3","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0090-9556(24)15041-6","article-title":"Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10","volume":"27","author":"Cheng","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.030999_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/03602530903209288","article-title":"Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system","volume":"42","author":"Court","year":"2010","journal-title":"Drug Met Rev"},{"key":"10.1124\/dmd.109.030999_bib5","doi-asserted-by":"crossref","first-page":"P46","DOI":"10.1016\/S0009-9236(03)90527-3","article-title":"Bazedoxifene acetate dose proportionality in healthy, postmenopausal women","volume":"73","author":"Ermer","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.109.030999_bib6","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2147\/TCRM.S3476","article-title":"Bazedoxifene for the prevention of postmenopausal osteoporosis","volume":"4","author":"Gennari","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1124\/dmd.109.030999_bib7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00002512-200724050-00002","article-title":"Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development","volume":"24","author":"Gennari","year":"2007","journal-title":"Drugs Aging"},{"key":"10.1124\/dmd.109.030999_bib8","first-page":"1086","article-title":"Bazedoxifene (Wyeth)","volume":"5","author":"Gruber","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/dmd.109.030999_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.5414\/CPP41331","article-title":"Review on raloxifene: profile of a selective estrogen receptor modulator","volume":"41","author":"Heringa","year":"2003","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.109.030999_bib10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1124\/jpet.103.063925","article-title":"Disposition mechanisms of raloxifene in the human intestinal Caco-2 model","volume":"310","author":"Jeong","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.109.030999_bib11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1124\/dmd.104.001883","article-title":"Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10","volume":"33","author":"Jeong","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.030999_bib12","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","article-title":"Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone"},{"key":"10.1124\/dmd.109.030999_bib13","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1124\/dmd.30.6.694","article-title":"Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance","volume":"30","author":"Kemp","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.030999_bib14","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/en.2005-0030","article-title":"Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity","volume":"146","author":"Komm","year":"2005","journal-title":"Endocrinology"},{"key":"10.1124\/dmd.109.030999_bib15","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/13543784.16.10.1663","article-title":"Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis","volume":"16","author":"Lewiecki","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/dmd.109.030999_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1358\/dof.2002.027.02.637843","article-title":"Bazedoxifene acetate","volume":"27","author":"Miller","year":"2002","journal-title":"Drugs Future"},{"key":"10.1124\/dmd.109.030999_bib17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study","volume":"23","author":"Miller","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1124\/dmd.109.030999_bib18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijpharm.2009.05.044","article-title":"Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9 and 1A10","volume":"378","author":"Mizuma","year":"2009","journal-title":"Int J Pharm"},{"key":"10.1124\/dmd.109.030999_bib19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-200342040-00004","article-title":"Pharmacokinetics of selective estrogen receptor modulators","volume":"42","author":"Morello","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.109.030999_bib20","doi-asserted-by":"crossref","first-page":"P43","DOI":"10.1016\/S0009-9236(03)90514-5b","article-title":"Absolute bioavailability of bazedoxifene acetate in healthy postmenopausal women","volume":"73","author":"Patat","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.109.030999_bib21","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/01.AOG.0000163253.27610.b9","article-title":"Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women","volume":"105","author":"Ronkin","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1124\/dmd.109.030999_bib22","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1124\/dmd.109.030999_bib23","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1345\/aph.1H428","article-title":"Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis","volume":"41","author":"Stump","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1124\/dmd.109.030999_bib24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/13543776.16.5.559","article-title":"Estrogen receptor modulator review","volume":"16","author":"Ullrich","year":"2006","journal-title":"Expert Opin Ther Patents"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624024589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624024589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.109.030999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:51:13Z","timestamp":1739897473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624024589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0090955624024589"],"URL":"https:\/\/doi.org\/10.1124\/dmd.109.030999","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Vitro Metabolism, Permeability, and Efflux of Bazedoxifene in Humans","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.109.030999","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}